SSEA3 and CD105 positivity are associated with the treatment potency of human neural crest-derived nasal turbinate stem cells for Alzheimer's disease.
Overview
- Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea,222 Banpo-daero Seocho-gu, Seoul, 09591 Republic of Korea
- Department of Neurosurgery, College of Medicine, St. Vincent’s Hospital, The Catholic University of Korea,93 Jungbu-daero, paldal-gu, Suwon-si, Seoul, 16247 Republic of Korea
- Department of Life Science, Dongguk University,30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620 Republic of Korea
- Institute of Catholic Integrative Medicine (ICIM), Incheon St. Mary’s Hospital, The Catholic University of Korea,56 Dongsu-ro, Bupyeong-dong, Bupyeonggu, Incheon, 21431 Republic of Korea
- Department of Neurosurgery, Seoul St. Mary’s Hospital, The Catholic University of Korea,222 Banpo-daero Seocho-gu, Seoul, 09591 Republic of Korea
- Department of Psychiatry, Yeouido St. Mary’s Hospital, The Catholic University of Korea,10 63-ro Yeongdeungpo-gu, Seoul, 07345 Republic of Korea
Abstract
Background: Stem cells have the potential to treat Alzheimer’s disease (AD), but clinical outcomes are unpredictable due to inter-donor differences in stem cell properties. This study aimed to determine whether the pluripotency marker SSEA3 and the mesenchymal marker CD105 positivity are associated with the therapeutic efficacy of human neural crest-derived nasal turbinate stem cells (NTSCs) for AD.
Methods: The therapeutic effects of NTSCs obtained from different donors, with varying percentages of SSEA3+/
Results: NTSCs from different donors improved cognitive function and AD-related neuropathology to varying degrees, depending on the percentage of SSEA3+/
Conclusions: Our findings suggest that SSEA3/
Supplementary Information: The online version contains supplementary material available at 10.1186/
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data, not to its authors' code: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- figshare:31450364, at figshare; found in DataCite
- figshare:31450367, at figshare; found in DataCite
Data availability
The datasets generated and/
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 30 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 12 authors, 6 keywords, 11 MeSH terms, 3 funders, 84 references.
Cite
This paper
Lim, J. Y., Lee, J. E., Lee, M., Shim, H., Park, S. I., Park, S. A., Jeun, S.-S., Wang, S.-M., Kim, S., Yang, S. H., Lim, H. K., & Kim, S. W. (2026). SSEA3 and CD105 positivity are associated with the treatment potency of human neural crest-derived nasal turbinate stem cells for Alzheimer's disease. Translational neurodegeneration, 15(1), 8. https://
BibTeX
@article{lim2026ssea3,
author = {Lim, Jung Yeon and Lee, Jung Eun and Lee, Minho and Shim, Haewon and Park, Sang In and Park, Soon A. and Jeun, Sin-Soo and Wang, Sheng-Min and Kim, Sunghwan and Yang, Seung Ho and Lim, Hyun Kook and Kim, Sung Won},
title = {{SSEA3 and CD105 positivity are associated with the treatment potency of human neural crest-derived nasal turbinate stem cells for Alzheimer's disease}},
journal = {Translational neurodegeneration},
year = {2026},
month = mar,
volume = {15},
number = {1},
pages = {8},
publisher = {BMC},
issn = {2047-9158},
doi = {10.1186/
url = {https://
pmid = {41772709},
pmcid = {PMC12955099}
}
RIS
TY - JOUR
AU - Lim, Jung Yeon
AU - Lee, Jung Eun
AU - Lee, Minho
AU - Shim, Haewon
AU - Park, Sang In
AU - Park, Soon A.
AU - Jeun, Sin-Soo
AU - Wang, Sheng-Min
AU - Kim, Sunghwan
AU - Yang, Seung Ho
AU - Lim, Hyun Kook
AU - Kim, Sung Won
TI - SSEA3 and CD105 positivity are associated with the treatment potency of human neural crest-derived nasal turbinate stem cells for Alzheimer's disease
T2 - Translational neurodegeneration
J2 - Transl Neurodegener
PY - 2026
DA - 2026/
VL - 15
IS - 1
SP - 8
SN - 2047-9158
PB - BMC
DO - 10.1186/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1186/
"type": "article-journal",
"title": "SSEA3 and CD105 positivity are associated with the treatment potency of human neural crest-derived nasal turbinate stem cells for Alzheimer's disease",
"container-title": "Translational neurodegeneration",
"author": [
{
"family": "Lim",
"given": "Jung Yeon"
},
{
"family": "Lee",
"given": "Jung Eun"
},
{
"family": "Lee",
"given": "Minho"
},
{
"family": "Shim",
"given": "Haewon"
},
{
"family": "Park",
"given": "Sang In"
},
{
"family": "Park",
"given": "Soon A."
},
{
"family": "Jeun",
"given": "Sin-Soo"
},
{
"family": "Wang",
"given": "Sheng-Min"
},
{
"family": "Kim",
"given": "Sunghwan"
},
{
"family": "Yang",
"given": "Seung Ho"
},
{
"family": "Lim",
"given": "Hyun Kook"
},
{
"family": "Kim",
"given": "Sung Won"
}
],
"container-title-short":
"volume": "15",
"issue": "1",
"page": "8",
"DOI": "10.1186/
"PMID": "41772709",
"PMCID": "PMC12955099",
"ISSN": "2047-9158",
"publisher": "BMC",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
3,
3
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1002/adhm.202504889 [code]
- Mapping the Cerebral Organoid Landscape: A Systematic Review of Preclinical 3D Models in Neuroscience.Journal: Advanced healthcare materialsIn common: 5 references
- [2] doi:10.1101/gr.280436.125 [code]
- Cell type-specific gene regulatory atlas prioritizes drug targets and repurposable medicines in Alzheimer's disease.Journal: Genome researchIn common: Alzheimer's / dementia, 3 references
- [3] doi:10.1038/s41467-026-69866-3 [code]
- Selective weakening of population-coupled synaptic activity in vivo in a mouse model of amyloid-beta pathology.Journal: Nature communicationsIn common: Alzheimer's / dementia, mouse, 2 references
- [4] doi:10.1038/s41467-026-74817-z [code]
- Early-Stage Corticostriatal Hyperactivity Impairs Cognitive Flexibility Alongside Striatal Cholinergic Dysfunction in an Alzheimer's Disease Model.Journal: Nature communicationsIn common: Alzheimer's / dementia, mouse, 2 references
- [5] doi:10.1038/s41593-026-02267-3 [code]
- Spatial proteomic analysis in human Alzheimer's disease brains enables identification of microenvironment-depende
nt microglial cell states. Journal: Nature neuroscienceIn common: Alzheimer's / dementia, 2 references - [6] doi:10.1016/j.apsb.2026.07.009
- Neutrophil-mediated BDNF delivery for the treatment of moderate to severe Alzheimer's disease.Journal: Acta pharmaceutica Sinica. BIn common: Alzheimer's / dementia, mouse, 2 references
- [7] doi:10.1002/ana.78193 [code]
- Chronological Diagnostic Algorithm Predicting Neuropathology in Parkinsonism.Journal: Annals of neurologyIn common: Alzheimer's / dementia, 2 references
- [8] doi:10.1038/s41588-026-02709-5
- PLCG2 downregulation impairs synaptic function and increases Alzheimer's disease hallmarks in neuronal cultures.Journal: Nature geneticsIn common: Alzheimer's / dementia, mouse, 2 references
- [9] doi:10.1186/s13024-026-00948-y
- Dual orexin receptor antagonism with lemborexant enhances microglial clearance of β-amyloid in mice.Journal: Molecular neurodegenerationIn common: Alzheimer's / dementia, mouse, 2 references
- [10] doi:10.1016/j.nbas.2026.100164
- Single-cell transcriptomic analysis reveals age-related remodeling of brain endothelial cells.Journal: Aging brainIn common: Alzheimer's / dementia, mouse, 2 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.
Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.